News

Actavis buying Durata Therapeutics for $616.4M

By Sun-Times Wire

Specialty pharmaceutical company Actavis is buying Chicago-based Durata Therapeutics Inc. for about $616.4 million to help bolster its infectious disease portfolio. One of Durata’s key products is Dalvance for injection, an IV antibiotic for acute bacterial skin and skin structure infections. Dalvance was approved by the Food and Drug Administration in May.

Read more at Newsfeed.

Next Up In News

5 North Side businesses robbed in just over 2 hours overnight

Some key dates in Mayor Brandon Johnson's first year in office

At Loyola, other four-year colleges, a chance to earn a two-year associate degree as a start

New Chicago-based company Global Tetrahedron wants to make The Onion great again

Amgen plows ahead with costly, highly toxic cancer dosing despite FDA challenge

The ups and downs of Mayor Brandon Johnson's roller coaster first year

The Latest

A student walks past Loyola University's Arrupe College building.

Education

At Loyola, other four-year colleges, a chance to earn a two-year associate degree as a start

The aim is to give students who might not initially see themselves going to a four-year school a boost that might help them eventually get a bachelor’s degree, as few two-year students do now.

By Matt Krupnick | The Hechinger Report

Dear Abby

Dear Abby: You helped cause our divorce, dad tells teen daughter

Girls says the man is angry that she stood up for her mom in a disagreement about the couple’s sex and drinking habits.

By Abigail Van Buren

Outdoors

Kids standing in Rock Creek dipping test tubes around

Trout Unlimited’s Trout In The Classroom teaches young students about fish and the aquatic environment, capped by a day trip to get all wet.

By Dale Bowman

Outdoor dining is allowed on a stretch of Clark Street in River North through Nov. 18.

Other Views

Clark Street closures for outdoor dining were great during the pandemic. Now? Not so much.

Businesses and neighborhood associations in River North and nearby want the city to end the dining program because of traffic congestion, delays to first responders and other headaches caused by closing off a major street artery, a local restaurant executive writes.

By Korina Sanchez

Amgen headquarters in Thousand Oaks, California.

The Watchdogs

Amgen plows ahead with costly, highly toxic cancer dosing despite FDA challenge

High doses become routine patient care even when they make patients so ill that they skip doses or stop taking the drugs. “There’s a gap in FDA’s authority that results in patients getting excess doses of a drug at excess costs,” says Dr. Mark Ratain, a University of Chicago oncologist.

By Arthur Allen | KFF Health News